# Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

> **NCT02723955** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 829 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** feladilimab (GSK3359609)
- **DRUG:** GSK3174998
- **DRUG:** Pembrolizumab
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel plus Carboplatin
- **DRUG:** Gemcitabine plus Carboplatin
- **DRUG:** Fluorouracil (5-FU) plus carboplatin or cisplatin
- **DRUG:** Dostarlimab
- **DRUG:** Cobolimab
- **DRUG:** Bintrafusp alfa

## Key facts

- **NCT ID:** NCT02723955
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-23
- **Primary completion:** 2023-07-05
- **Final completion:** 2023-07-05
- **Target enrollment:** 829 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723955, "Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02723955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*